News
-
-
-
COMMUNIQUÉ DE PRESSE
Immunic’s Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing
Immunic's Oral IMU-856 shows dose-dependent increase of GLP-1 in celiac disease patients, potential as oral weight management treatment. New data presented in webcast -
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Immunic Highlights 2024 Accomplishments and Upcoming Milestones
Immunic, Inc. highlights its 2024 accomplishments and upcoming milestones, including positive trial results for vidofludimus calcium in multiple sclerosis. Strengthened team and secured private placement for future growth -
